
- Volume 0 0
APhA SUPPORTS FDA RULES FOR DUAL STATUS
Organized pharmacy leaders urged theFDA to develop new rules clarifying theagency's power to approve dual statusdrugs—a move that could clear the pathfor the simultaneous marketing of pharmaceuticalsas both prescription andOTC products.
In urging the agency to act on thisissue, officials at the American PharmacistsAssociation (APhA) cited the recentupsurge in prescription to OTC switchesand the likelihood of even more Rx drugsbeing approved for nonprescription salein the near future. "As the number ofswitch applications increases, so will thepotential for active ingredients that maybest be simultaneously classified as botha prescription and an OTC, or placed insome type of in-between or transitioncategory," an APhA official said.
Articles in this issue
over 20 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsover 20 years ago
High Alert Insulin Binover 20 years ago
Hydase (hyaluronidase injection, USP)over 20 years ago
Humira (adalimumab)over 20 years ago
INVANZ (ertapenem for injection)over 20 years ago
Compounding HOTLINEover 20 years ago
Customer Guilty of Prescription Fraud by Supporting Friendover 20 years ago
Counterfeit Drugs: A Life-or-Death Problemover 20 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsover 20 years ago
Can You Read These Rxs?





































































































































